All In MedTech

FDA Clearance Tracker · DEN230061

allay Nerve Cap

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 20, 2026Latest source record: Jul 16, 2024 (this decision)Source: openFDAMethods & limitations

De NovoNew device type

Decided

Jul 16, 2024

De Novo granted

Time to decision

308 days

Received Sep 12, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

De Novo

Direct

Device class

Class II

The decision

FDA number
DEN230061
Device name
allay Nerve Cap
Applicant location
Lost Gatos, CA
Received
Sep 12, 2023
Decided
Jul 16, 2024
Decision
De Novo granted
Submission type
Direct

Device type

Device class
Class II
Regulation
21 CFR 882.5260

Every decision under product code SBG

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Tulavi Therapeutics

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.